Plandai Biotechnology, Inc. Announces Commencement of Clinical Trials Using Phytofare Topical Product
SEATTLE, WA--(Marketwired - Sep 5, 2013) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has engaged North-West University, a leading medical research facility in Potchefstroom, South Africa, to conduct several clinical studies involving Phytofare™ Pheroid™ Topical Catechin Complex ("ph2TM"), a new topical cream based on the nano-entrapment technology developed by Prof. Anne Grobler at NWU and recently licensed to Plandaí for human and animal use.
The first of two commissioned studies, which commenced August 30, 2013, will test the moisturizing effects of Phytofare™ Pheroid™ Topical Catechin Complex on 35 human volunteers. A second study, also commenced August 30th on 35 human subjects, is testing the anti-inflammatory benefits of the product. A third human study will start later in the year to explore the anti-aging properties of Phytofare™ Pheroid™ Topical Catechin Complex. The topical cream is expected to be marketed as an ingredient in various skin care products.
The Pheroid™ technology, developed in conjunction with North-West University, allows Phytofare™ particles to be entrapped in a long-chain fatty acid, which has been previously shown to enhance absorption in both topical and oral preparations.
Roger Duffield, Chairman and Chief Executive Officer of Plandaí Biotechnology, commented, "We are enthusiastic about the potential for ph2TM Topical Catechin Complex in the nutriceutical market space. We've fielded multiple inquiries from large skin care product manufacturers interested in seeing the known benefits of green tea catechins transferred into a topical solution that can penetrate through the various tissue levels and be absorbed at the cellular level. We envision this product being incorporated into products ranging from skin rejuvenation to anti-aging to after shave."
The trials are expected to take approximately three months leading up to anticipated market release during the first quarter of 2014.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
Email: Email Contact